Analysts Set Revance Therapeutics Inc (NASDAQ:RVNC) Target Price at $34.73

Shares of Revance Therapeutics Inc (NASDAQ:RVNC) have been given an average recommendation of “Buy” by the fourteen research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $34.73.

RVNC has been the subject of several analyst reports. Zacks Investment Research raised shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 9th. BidaskClub downgraded shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 17th. Barclays initiated coverage on shares of Revance Therapeutics in a report on Tuesday, June 11th. They set an “overweight” rating and a $28.00 price target for the company. ValuEngine raised shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, William Blair reissued an “outperform” rating on shares of Revance Therapeutics in a report on Tuesday, August 6th.

NASDAQ:RVNC opened at $10.89 on Tuesday. The company has a 50-day moving average of $11.66 and a 200-day moving average of $13.16. The company has a market capitalization of $480.25 million, a price-to-earnings ratio of -2.76 and a beta of 1.16. Revance Therapeutics has a 52 week low of $9.88 and a 52 week high of $27.80. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.59 and a current ratio of 5.59.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.86). Revance Therapeutics had a negative net margin of 3,745.97% and a negative return on equity of 79.28%. Sell-side analysts forecast that Revance Therapeutics will post -3.73 EPS for the current year.

Hedge funds have recently made changes to their positions in the stock. DekaBank Deutsche Girozentrale acquired a new stake in Revance Therapeutics in the 2nd quarter valued at about $1,010,000. Rice Hall James & Associates LLC increased its position in Revance Therapeutics by 252.7% in the 1st quarter. Rice Hall James & Associates LLC now owns 117,068 shares of the biopharmaceutical company’s stock valued at $1,845,000 after acquiring an additional 83,875 shares in the last quarter. Aperio Group LLC increased its position in Revance Therapeutics by 166.2% in the 2nd quarter. Aperio Group LLC now owns 34,551 shares of the biopharmaceutical company’s stock valued at $448,000 after acquiring an additional 21,570 shares in the last quarter. Hikari Power Ltd acquired a new stake in Revance Therapeutics in the 2nd quarter valued at about $1,039,000. Finally, BNP Paribas Arbitrage SA acquired a new stake in Revance Therapeutics in the 1st quarter valued at about $125,000. 95.45% of the stock is owned by hedge funds and other institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.

Recommended Story: Sell-Side Analysts

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.